Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06794268 | RECRUITING | Follicular Lymphoma

A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
Sponsor:

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Brief Summary:

The purpose of this study is to characterise the long-term safety of lisocabtagene maraleucel, focusing on patients treated in the approved follicular lymphoma (FL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities

Condition or disease

Follicular Lymphoma

Intervention/treatment

Lisocabtagene maraleucel

Study Type : OBSERVATIONAL
Estimated Enrollment : 300 participants
Official Title : Non-interventional Cohort Study of Patients Treated With Liso-cel (Lisocabtagene Maraleucel) for Relapsed/Refractory Follicular Lymphoma in the Postmarketing Setting
Actual Study Start Date : 2025-02-04
Estimated Primary Completion Date : 2044-08-31
Estimated Study Completion Date : 2044-08-31

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • • Participants must have been treated in the post-marketing setting with at least 1 infusion of lisocabtagene maraleucel (liso-cel) used for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL), including FL Grade 1, Grade 2 and Grade 3a, within the FDA-approved indication and dosage per the United States Prescribing Information (USPI) and product specifications approved for commercial release in the USA
Exclusion Criteria
  • * Participants known to be participating in investigational studies at the time of liso-cel, infusion
  • * Participants treated with liso-cel for the treatment of R/R FL Grade 3b
  • * Participants treated with non-conforming chimeric antigen receptor (CAR) T-cell product
A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

Location Details

NCT06794268

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Wisconsin

CIBMTR

Milwaukee, Wisconsin, United States, 53226